FAS.research's Network Healthcare Strategy Solution enables you to see your market as a network where KOLs, KDMs and nontraditional stakeholders are connected, influence each other and ultimately determine the success of your therapy. FAS.research uncovers, maps and scientifically measures people, networks and key factors that have the most influence on your sales goals. This approach enables you to optimize the allocation of sales, marketing or advocacy resources with confidence - regardless of where your therapy is in the product development life cycle.
FAS.research's methodology is based on a proprietary application of social network analysis, a scientific discipline that enables FAS.research to offer you an unmatched level of precision in measuring influence in your market, from the prescriber to the regulator level.
FAS.research takes the guesswork out of determining who is most influential and how to access them. Our methods are superior to traditional quantitative methods because we use the science of networks to measure influence, trust and the value of access points within social networks. Unlike other KOL solutions, FAS.research gives you complete KOL coverage segmenting KOLs by influence, geography and expertise. In addition, FAS.research can predict future KOLs and even drug evaluation committee selections using proprietary data mining algorithms.
KOL application examples:
- Developed a comprehensive KOL strategy for a global pharmaceutical company that segmented a large European country’s KOLs by influence level, network role, geography and expertise. Networking action plans, indices and interactive visualization tools were given to employees at all levels of the firm including the CEO, lobbyists, medical directors and local sales representatives to accelerate penetration of key therapies
- Predicted drug evaluation committee selection before the committee was formed to help a global pharmaceutical company get a head start on lobbying
- Identified, measured the network value of and mapped the KOLs critical to the launch of a targeted oncology drug for a global pharmaceutical company